The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.

Authors: Atwal A; Snowsill T; Dandy MC et al.
Source: International journal of cancer [Int J Cancer] 2022 Jun 15. Date of Electronic Publication: 2022 Jun 15.
Abstract:
Ovarian cancer (OC) is the least survivable gynecological malignancy and presents late. Five-year survival for OC is around 45% increasing the need for innovative treatments. Checkpoint inhibitors have shown significant clinical efficacy in mismatch repair deficient (MMRd) cancers and could be a powerful treatment in OC. However, their application in OC is limited due to the lack of data on the prevalence of MMRd. The aim of our study was to conduct a systematic review of the literature and meta-analysis to provide an accurate estimate of the prevalence of MMRd in OC.

Full text available here